BLRX logo

BioLineRx Ltd. Stock Price

TASE:BLRX Community·₪33.9m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

BLRX Share Price Performance

₪0.013
-0.01 (-31.58%)
₪0.013
-0.01 (-31.58%)
Price ₪0.013

BLRX Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

6 Risks
2 Rewards

BioLineRx Ltd. Key Details

US$1.2m

Revenue

US$230.0k

Cost of Revenue

US$950.0k

Gross Profit

US$2.1m

Other Expenses

-US$1.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.00045
80.51%
-99.58%
38.3%
View Full Analysis

About BLRX

Founded
2003
Employees
22
CEO
Philip Serlin
WebsiteView website
www.biolinerx.com

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company’s pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Recent BLRX News & Updates

Recent updates

No updates